| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 6,554 | 6,053 |
| Gross Profit | 3,837 | 3,523 |
| Pretax Income | 1,132 | 1,076 |
| Net Income | 1,235 | 908.00 |
| Diluted EPS | 1.75 | 1.27 |
- Net Income YoY
- +36.0%
Key highlights
- Quarterly revenue rose to $6,554 million from $6,053 million in the prior year
- Net income surged 36.0% year-over-year to reach $1,235 million
- Diluted earnings per share increased to $1.75 compared to $1.27 in Q3 2025
- Gross profit climbed to $3,837 million, reflecting sustained operational efficiency
- Management raised full-year 2026 adjusted diluted EPS guidance to $8.57–$8.62
How the Period Went
Danaher reported a significant expansion in its financial performance for the third quarter of 2026. Revenue climbed to $6,554 million, up from $6,053 million in the same period last year, marking a consistent upward trend following revenues of $6.00 billion in the first quarter and $6.30 billion in the second quarter. Net income experienced a substantial 36.0% increase to $1,235 million, compared to $908.00 million previously, while diluted earnings per share rose to $1.75 from $1.27. These results were bolstered by a gross profit of $3,837 million, reflecting the company's ability to scale operations effectively alongside its increasing revenue base.
Margins and Profitability
Profitability metrics remained robust as the company navigated a period of intense capital deployment. While pretax income rose to $1,132 million from $1,076 million, the sharper rise in net income suggests a favorable impact from continuing operations and tax positioning. The company’s acquisition strategy was a primary driver of balance sheet evolution, with $9.9 billion spent on cash acquisitions during the first nine months of 2026. This activity significantly increased goodwill and intangible assets, which management leverages to enhance long-term margins. Net earnings from continuing operations for the nine-month period reached $3.1 billion, up from $2.4 billion in the prior year.
Business Overview
As a global science and technology leader, Danaher operates primarily within the Biotechnology, Life Sciences, and Diagnostics segments. The company provides essential tools, consumables, and software that support the development of life-saving therapies and clinical diagnostics. Serving diverse end markets including pharmaceutical companies, hospitals, and research institutions, Danaher utilizes the Danaher Business System (DBS) to drive continuous improvement. This operational framework allows the company to integrate complex acquisitions, such as those executed this year, while maintaining a focus on high-recurring revenue streams from consumables, which provide stability against broader macroeconomic fluctuations in capital equipment spending.
Financial Context and Industry Landscape
With a market capitalization of $157.6 billion and a P/E ratio of 39.97, Danaher maintains a premium valuation reflective of its leadership in the healthcare sector. The company’s RSI of 56.1 indicates a stable technical position following a 10.21% price increase over the last quarter. In the broader industry, Danaher faces a competitive landscape alongside peers like Thermo Fisher Scientific, where demand for bioprocessing and genomic tools remains a primary growth engine. Danaher’s backlog, which stood at approximately $7.5 billion as of June 26, 2026, according to SEC filings, provides visibility into future revenue as the sector adapts to evolving R&D budgets.
Up 2.5% since our story on 21 Oct: $224.24 when we broke it → $229.91 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $224.43 |
|---|---|
| 20 Oct | $224.24 |
| 21 Oct | $233.86 |
| 22 Oct | $229.75 |
| 23 Oct | $230.50 |
| 26 Oct | $232.97 |
| 27 Oct | $232.00 |
| 28 Oct | $234.07 |
| 29 Oct | $236.98 |
| 30 Oct | $232.23 |
| 2 Nov | $227.97 |
| 3 Nov | $230.11 |
| 4 Nov | $234.93 |
| 5 Nov | $226.34 |
| 6 Nov | $230.25 |
| 9 Nov | $235.12 |
| 10 Nov | $236.11 |
| 11 Nov | $235.31 |
| 12 Nov | $232.16 |
| 13 Nov | $233.02 |
| 16 Nov | $229.91 |
| Date | Announcement | Amount |
|---|---|---|
| 21 Jul 2026 | Q2 2026 revenuesSource: prnewswire.com | $6.30 Billion |
| 21 Jul 2026 | Full-year 2026 adjusted diluted EPS guidance of $8.45 to $8.60Source: investors.danaher.com | – |
| 21 Apr 2026 | Q1 2026 revenuesSource: prnewswire.com | $6.00 Billion |
| 21 Apr 2026 | Full-year 2026 adjusted diluted EPS guidance raisedSource: prnewswire.com | – |
| Share price | $224.24 |
|---|---|
| Market cap | $157.6B |
| Revenue (annual) | $24.6B |
| P/E (TTM) | 40.0× |
| 1-month price change | +6.06% |
| Sector | HealthcareDiagnostics & Research |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Danaher Corporation announcing third quarter 2026 financial results.
Track DANAHER CORP /DE/ live
Get the next DANAHER CORP /DE/ SEC filing seconds after it lands.



